HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects.

Abstract
CHF5074 has been shown to inhibit brain β-amyloid deposition and attenuate memory deficits in different transgenic mice models of Alzheimer disease. We evaluated the safety, pharmacokinetics, and pharmacodynamics of 3 ascending dose regimens of CHF5074 (200, 400, and 600 mg/d for 14 d) in a double-blind, placebo-controlled, parallel group study involving 48 healthy subjects. Plasma, urine, and cerebrospinal fluid (CSF) samples were collected for measuring drug and main metabolite concentrations and potential biomarkers of pharmacodynamic activity (β-amyloid1-40, β-amyloid1-42, soluble CD40 ligand, and tumor necrosis factor-α). All subjects completed the study, and no serious or severe adverse events were reported. The maximum tolerated dose was close to 600 mg/d with mild diarrhea being the most frequent adverse event at this dose. CHF5074 reached peak plasma levels 2 to 3 hours after drug administration and then was slowly eliminated (t(1/2z)=30 h) in the urine as glucoronide. Systemic exposure to the drug appeared to be dose-proportional with a 2-fold accumulation ratio at steady state. Metabolite plasma levels peaked at 4 to 5 hours and accounted for about 25% of the parent compound. Drug levels in the CSF were dose-proportional. The drug dose-dependently lowered the levels of the soluble CD40 ligand, a marker of microglia activation, in both plasma and CSF samples.
AuthorsBruno P Imbimbo, Enrico Frigerio, Massimo Breda, Francesco Fiorentini, Mercedes Fernandez, Sandra Sivilia, Luciana Giardino, Laura Calzà, Dottie Norris, Daniela Casula, Magdy Shenouda
JournalAlzheimer disease and associated disorders (Alzheimer Dis Assoc Disord) 2013 Jul-Sep Vol. 27 Issue 3 Pg. 278-86 ISSN: 1546-4156 [Electronic] United States
PMID22922591 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • 1-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid
  • Cyclopropanes
  • Enzyme Inhibitors
  • Neuroprotective Agents
  • Flurbiprofen
Topics
  • Adult
  • Cyclopropanes (adverse effects, blood, pharmacokinetics)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Enzyme Inhibitors (adverse effects, blood, pharmacokinetics)
  • Flurbiprofen (adverse effects, analogs & derivatives, blood, pharmacokinetics)
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Neuroprotective Agents (adverse effects, blood, pharmacokinetics)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: